Remove Clinic Remove Government Remove Information Remove Lab Testing
article thumbnail

Outcomes of Guidelines from Health Technology Assessment Organizations: A Systematic Mixed Studies Review [Systematic review, meta-analysis, or scoping review]

Annals of Family Medicine

Context: Health Technology Assessment (HTA) organizations determine the value of health technologies such as medical devices, lab tests, or medications. learning), the use of guideline-based information in clinical practice, and subsequent patient health outcomes. Health organization outcomes.

article thumbnail

The Incredible Shrinking Exemption: FDA Final CDS Guidance Would Significantly Narrow the Scope of Exempt Clinical Decision Support Software Under the Cures Act

FDA Law

Javitt — On September 28, 2022, the FDA issued the long anticipated final Clinical Decision Support Software Guidance (CDS Guidance), which replaces the revised draft guidance document from 2019. Criterion 2 : Non-Device CDS software functions display, analyze or print medical information about a patient or other medical information.

Clinic 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Podcast: AI, innovation, and value-based care in medicine

Permanente Medicine

Contributing to this challenge is the exponential growth of information, an expanding population of older adults, and office visit documentation. Information is coming at clinicians, whether they be doctors, nurses, pharmacists, faster than ever, and there is a transparency that exists around us.

article thumbnail

District Court Interprets EKRA

FDA Law

In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. S&G Labs’ pay structure was important to the Court’s decision regarding the EKRA issue.

article thumbnail

District Court Interprets EKRA

FDA Law

In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. S&G Labs’ pay structure was important to the Court’s decision regarding the EKRA issue.